Pfizer

Investors need to own a specific number of Pfizer shares to achieve a target of $5,000 in yearly dividends.

Pfizer's stock continues to decline due to poor financial results, a failed late-stage clinical trial for a non-small cell lung cancer drug (sigvotatug vedotin) obtained through the $43 billion Seagen acquisition, and the recent departure of its CFO, David Denton, further compounded by upcoming patent expirations for key drugs like Eliquis.

Investors can calculate the number of Pfizer shares needed to achieve $5,000 in yearly dividends based on its current dividend payout.

Pfizer is a compelling dividend stock for long-term income investors due to its high 6.9% yield and depressed stock price, despite recent struggles with drug development and patent expirations.

Pfizer has declared a third-quarter 2026 dividend, signaling continued shareholder returns.

Pfizer's stock has fallen 57% from its 2021 high, but its 'obesity bet' could reset the stock positively by 2028.

Pfizer's stock, despite being currently undervalued and facing headwinds, presents an opportunity for long-term investors to build generational wealth due to its high dividend yield and pipeline potential.

Pfizer's shares dropped following the announcement of CFO Dave Denton's departure, prompting investor concerns about leadership stability and the successful execution of the company's 2026 revenue and adjusted EPS targets amidst ongoing patent expirations and cost control efforts.